معرفی
Olivier Elemento serves as Professor at Weill Cornell Medicine's Graduate School of Medical Sciences with primary appointments in Computational Biology. He directs the Englander Institute for Precision Medicine, serves as Associate Director of the Institute for Computational Biomedicine, and holds the position of Associate Program Director for the Clinical & Translational Science Center. His extensive institutional affiliations include Meyer Cancer Center, New York Genome Center (as Affiliate Member), Volastra Therapeutics (as Founder), OneThree Biotech (as Scientific Advisor and Co-Founder), and RLab NYC (as Faculty Committee member).
Elemento's research program integrates Big Data analytics with experimental approaches to revolutionize cancer prevention, diagnosis, and treatment. His lab specializes in ultrafast genome sequencing, proteomics, high-performance computing, mathematical modeling, and machine learning applications in oncology. Key research thrusts include systems biology of regulatory networks in blood cancers, cancer genomics and precision medicine, epigenomics of cancer, tumor genome evolution, and development of computational approaches for high-throughput experiments. His team developed ChIPseeqer, a widely used ChIP-seq analysis framework, and a machine learning algorithm for thyroid cancer detection licensed by Prolias Technologies.
Analysis of Elemento's recent publications reveals a strong focus on integrating multi-omics data with artificial intelligence to address critical challenges in cancer diagnostics and treatment. His work spans pan-cancer analyses, spatial biology, liquid biopsy development, and AI-driven clinical decision support systems. A notable trend is the application of foundation models and deep learning to diverse medical contexts from embryo selection to laryngoscopy, demonstrating his lab's commitment to translational computational biomedicine.
Elemento actively leads multiple collaborative initiatives including the Polyethnic-1000 project studying cancer in ethnically diverse populations and co-chairs the Very Rare Cancer Consortium with Dr. Harold Varmus. His lab maintains strong industry partnerships through biotech ventures focused on computational drug discovery and precision oncology applications.
The Elemento Lab operates at the intersection of computational science and clinical medicine, with physical locations at Weill Cornell Medicine and NewYork-Presbyterian Hospital. The lab maintains active collaborations across the Tri-Institutional community including Memorial Sloan Kettering Cancer Center and Rockefeller University, fostering a multidisciplinary environment that bridges basic science, computational innovation, and clinical application.
